Leerink Partners Maintained a Buy on Merck & Co (MRK)

Merck & Co., Inc. (NYSE:MRK) is one of the Most Undervalued S&P 500 Stocks to Buy Right Now. On August 26, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $107.

The analyst noted promising clinical trial results as one of the key reasons behind the bullish sentiment. Graybosch noted HARMONi-A, which showed that combining ivonescimab with chemotherapy significantly improved overall survival compared to chemotherapy alone. The analyst believes that this highlights the potential of VEGF-A/PD-(L)1 drug class in treating some lung cancers.

Moreover, ivonescimab offers durable benefits through VEGF-A antagonism. This is important because, unlike similar drugs like bevacizumab, it may avoid common side effects, making it a better option.

Merck & Co., Inc. (NYSE:MRK) is a global health care company that develops and sells prescription medicines, vaccines, and animal health products.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.